obesity research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-12. Anything still debated is marked as such rather than presented as settled.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
In 2019, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed evidence on fluvoxamine as part of its class-wide signal assessment and recommended that product labels for all SSRIs and SNRIs be updated to state that sexual dysfunction may be long-lasting even after treatment is stopped. Health Canada followed with similar label updates in 2021. In 2024, Australia's Therapeutic Goods Administration aligned all SSRI and SNRI product information to reflect this risk; fluvoxamine was among the products requiring updated warnings.
In October 2020, Gilead and HHS announced that HHS was relinquishing control over remdesivir allocation because production of the drug had finally caught up with US domestic demand. AmerisourceBergen will remain the sole distributor of Veklury in the US through the end of 2020. On 22 October 2020, the FDA approved remdesivir and also revised the EUA to permit the use of remdesivir for treatment of suspected or laboratory confirmed COVID‑19 in hospitalized children weighing 3.5 kilograms (7.7 lb) to less than 40 kilograms (88 lb) or hospitalized children less than twelve years of age weighing at least 3.5 kilograms (7.7 lb). This decision was criticized for an alleged lack of previous consultation on part of the FDA given the complications of antiviral drug issues. In November 2020, the FDA issued an EUA for the combination of baricitinib with remdesivir, for the treatment of suspected or laboratory-confirmed COVID‑19 in hospitalized people two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The data supporting the EUA for baricitinib combined with remdesivir are based on a randomized, double-blind, placebo-controlled clinical trial (ACTT-2), which was conducted by the National Institute of Allergy and Infectious Diseases (NIAID). The EUA was issued to Eli Lilly and Company. Remdesivir received approval from the US Food and Drug Administration (FDA) in October 2020, for use in adults and children twelve years and older requiring hospitalization for treatment of severe COVID‑19 infections.
The increase in γGCS causes an increased production of arsenite triglutathionine (As(SG)3) an important adduct that is taken up by either multidrug associated protein 1 (MRP1) or MRP2 which remove the arsenic out of the cell and into bile for excretion. This adduct can also decompose back into inorganic arsenic. Of particular note in the excretion of arsenic is the multiple methylation steps that take place which may increase the toxicity of arsenic due to MMeAsIII being a potent inhibitor of glutathione peroxidase, glutathione reductase, pyruvate dehydrogenase, and thioredoxin reductase.
Sources: en.wikipedia.org
While reef-forming corals are almost entirely restricted to warm and shallow marine waters, other cnidarians can be found at great depths, in polar regions, and in freshwater. Cnidarians are a very ancient phylum, with fossils having been found in rocks formed about 580 million years ago during the Ediacaran period, preceding the Cambrian Explosion. Other fossils show that corals may have been present shortly before 490 million years ago and diversified a few million years later. Molecular clock analysis of mitochondrial genes suggests an even older age for the crown group of cnidarians, estimated around 741 million years ago, almost 200 million years before the Cambrian period, as well as before any fossils. Recent phylogenetic analyses support monophyly of cnidarians, as well as the position of cnidarians as the sister group of bilaterians.
=== Dreamcast port === On February 14, 2000, Sierra announced that a port of Half-Life for the Dreamcast console was in development by Captivation Digital Laboratories with Valve and Gearbox Software. It would feature improvements including higher-polygon character models and new lighting effects. Gearbox, who had developed Opposing Force, created a new single-player campaign for the port, Half-Life: Blue Shift, focusing on the security guard Barney. The port was delayed to September 2000, then November, when game publications began to receive early copies for review. Reception was mixed, with criticism for the inconsistent frame rate, long loading times and lack of online play. Sierra planned to release a version with online multiplayer using SegaNet. The Gearbox CEO, Randy Pitchford, said he suggested adding multiplayer modes and mods from the Windows version, including Team Fortress Classic and the multiplayer modes from Opposing Force. Sierra delayed the port again and said they hoped to finish development that year. On March 29, 2001, Sierra announced that Blue Shift would be released for Windows along with the character models developed for the Dreamcast version, as part of the Half-Life High Definition Pack. On June 16, 2001, four days after the release of Blue Shift, Sierra announced that it had canceled the Dreamcast port, citing "changing market conditions". It was weeks away from its release date and virtually complete. In 2013, a late version of the Dreamcast port leaked online, featuring complete versions of Half-Life and Blue Shift.
==== H2 gas ==== The δD of atmospheric H2 is around +180‰, the biggest δD known for natural terrestrials (mole fraction 2H: 183.8 ppm). The δD of natural gas from a Kansas well is around −836‰ (mole fraction 2H: 25.5 ppm) In electrolysis of water, hydrogen gas is produced at the cathode, but incomplete electrolysis of water may cause isotopic fractionation leading to enrichment of 2H in the sample water and the production of hydrogen gas with deuterium components.
Sources: en.wikipedia.org
In 2018, Stein opened a second Rick Stein at Bannisters in Salamander Bay in Port Stephens, with his second wife, Sarah. Stein has become a popular television presenter on food programmes. After appearing once as a guest chef in Keith Floyd's 1985 series Floyd on Fish and in his 1986 series Floyd on Food, he was offered the chance to present his own series – like the "travelogue" style of cookery show pioneered by Floyd – on BBC television, using Floyd's producer and director David Pritchard. His shows have included Rick Stein's Taste of the Sea, Fruits of the Sea, Seafood Odyssey, Fresh Food, Seafood Lovers' Guide, Food Heroes, French Odyssey, Mediterranean Escapes, Far Eastern Odyssey, Rick Stein's Spain and Rick Stein's India. In the last five series, he set out in search of the best in the region's foods. Stein was often accompanied by his Jack Russell Terrier, Chalky, until his death in 2007. So popular was Chalky that Sharp's Brewery named two speciality beers after him. A book has accompanied each series, and Stein's book English Seafood Cookery won the Glenfiddich Award for Food Book of the Year in 1989. Stein was awarded the OBE in the 2003 New Year Honours for services to tourism in Cornwall and the CBE in the 2018 New Year Honours for services to the economy. On 22 June 2020, it was confirmed that Stein's restaurant in Porthleven, Cornwall, would close permanently due to the COVID-19 pandemic. The restaurant had been closed since March 2020. In July 2020, it was announced that chef Michael Caines would take over the restaurant.
On March 20, 1976, Marrow's high school girlfriend Adrienne gave birth to their daughter LeTesha Marrow, and they continued attending high school while raising her. While filming Breakin' in 1984, he met his second girlfriend Darlene Ortiz, who was at the club where the film was shot. They began a relationship and Ortiz was featured on the covers of Rhyme Pays and Power. Ice-T and Ortiz had a son, Ice Tracy Marrow Jr., on November 23, 1991; Ice Marrow, aka "Little Ice", became a backing vocalist with Body Count in time for the recording of their album Carnivore. Ice-T married swimsuit model Coco Austin in January 2002. In celebration of their impending ninth wedding anniversary, the couple renewed their wedding vows on June 4, 2011. As of 2006, they owned a penthouse apartment in North Bergen, New Jersey. In 2012, they were building a five-bedroom house in Edgewater, New Jersey, that was expected to be completed by the end of the year. In 2015, the couple had their first child together, a daughter. Ice-T has stated on numerous occasions that he is a teetotaler, and lives a straight edge lifestyle. He is a long time practitioner of Brazilian Jiu-Jitsu and boxing, and is a big fan of the UFC.
In 2003 Håkan Steiner and coworkers and Roman Dziarski and coworkers discovered that mouse and human PGLYRP2 (PGRP-L) proteins encoded by the mouse and human PGLYRP2 genes are N-acetylmuramoyl-L-alanine amidases. Recombinant and native human PGLYRP2 proteins were then further shown to be identical with the previously identified and purified serum NAMLAA.
hydrogenation Any chemical reaction between molecular hydrogen (H2) and another chemical species, typically resulting in the reduction or saturation of the other species by the addition of one or more pairs of hydrogen atoms to a compound or element. The presence of a catalyst is usually required for hydrogenation reactions to occur; non-catalytic hydrogenation takes place only at extreme temperatures.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.